Activity and safety of KEES - an oral multi-drug chemo-hormonal metronomic combination regimen in metastatic castration-resistant prostate cancer.

BMC Cancer · 2023 · PMC10074662 · PMID 37016322

Europe PMC DOI

hedged sentence

0.0520

closest p · 1.0× alpha

0.0520

boldest claim

The sentences

borderline significantp = 0.052so close (0.05 < p ≤ 0.1)

None of the patients treated without estramustine experienced a PSA reduction of > 50%, with the difference being borderline significant (35% vs. 0%, p = 0.052).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.